We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Arrowhead Pharmaceuticals Inc | NASDAQ:ARWR | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.31 | 1.28% | 24.44 | 24.16 | 25.69 | 25.235 | 24.12 | 25.02 | 630,837 | 01:00:00 |
From May 2019 to May 2024
By Colin Kellaher
Arrowhead Pharmaceuticals Inc. (ARWR) on Wednesday said it earned a $25 million milestone payment after a unit of Johnson & Johnson (JNJ) began a phase 2b combination study in patients with chronic hepatitis B infection.
The Pasadena, Calif., drug developer said J&J's Janssen Pharmaceuticals unit has begun dosing in the study of different combination regimens, including JNJ-3989, formerly ARO-HBV.
Arrowhead in October agreed to work with Janssen to develop and commercialize ARO-HBV as part of a license and collaboration agreement potentially worth more than $3.7 billion to Arrowhead.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
August 28, 2019 09:07 ET (13:07 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year Arrowhead Pharmaceuticals Chart |
1 Month Arrowhead Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
